OptimUM-01 pravastatin and drug interaction cocktail substudies: planned pharmacokinetic outcome measures
OptimUM-01 pravastatin and drug interaction cocktail substudies: exclusion of interacting drugs and probe substrates
“Taken drugs that interfere with the absorption, metabolism, or elimination of pravastatin” (opens the source at this quote in a new tab)
“Treatment with bupropion, repaglinide, flurbiprofen, omeprazole, esomeprazole, midazolam, and dabigatran etexilate within 7 days prior to Cycle 1 Day -1.” (opens the source at this quote in a new tab)
“Intake of any strong or moderate inhibitor of CYP2B6, CYP2CI, CYP2C9, CYP2C10 and OAT3 is prohibited within 7 days or within 5 half-lives, whichever is longer, of Cycle 1 Day -1.” (opens the source at this quote in a new tab)
Results of the pravastatin and drug interaction cocktail substudies
No evidence found.
Overlapping adverse events of darovasertib and crizotinib in the OptimUM-01 first-line cohort
Crizotinib label: CYP3A substrates
Crizotinib label: drugs that prolong the QT interval or cause bradycardia
Crizotinib label: in vitro inhibition of CYP enzymes and transporters
“CYP Enzymes: Crizotinib inhibits CYP2B6 in vitro. Crizotinib does not inhibit CYP1A2, CYP2C8, CYP2C9, CYP2C19, or CYP2D6.” (opens the source at this quote in a new tab)
“Crizotinib does not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A.” (opens the source at this quote in a new tab)
“Transporters: Crizotinib inhibits P-gp, organic cation transporter (OCT) 1, and OCT2.” (opens the source at this quote in a new tab)